U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H23NO2S
Molecular Weight 281.4153
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OSU-6162

SMILES

CCCN1CCC[C@]([H])(C1)c2cccc(c2)S(=O)(=O)C

InChI

InChIKey=GZVBVBMMNFIXGE-CQSZACIVSA-N
InChI=1S/C15H23NO2S/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3/t14-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H23NO2S
Molecular Weight 281.4153
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

PNU-96391A (known as OSU6162) is a weak dopamine (DA) D(2) receptor antagonist with behavioral stabilizing properties. OSU6162 seem to act as stabilizers not only on dopaminergic, but also on serotonergic brain signaling (partial agonist on 5-HT2A receptor). OSU6162 in a phase II European clinical trial in treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. One of the isomer of OSU 6162, has promise for treating Parkinson's disease, Huntington's disease and schizophrenia, but both enantiomers of OSU 6162 had dual effects on behavior, stimulating locomotor activity in 'low activity' animals and inhibiting locomotor activity in 'high activity' animals.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
447.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.245 μM
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.0178 μM
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.543 μM
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.1 μM
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.19 μM
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.2 μM
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.372 μM
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.038 μM
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2.27 μM × h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.24 μM × h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.18 μM × h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.53 μM × h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
14.8 μM × h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.87 μM × h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.69 μM × h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.223 μM × h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.89 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.94 h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.32 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.37 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.66 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.39 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.33 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.77 h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
45 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 45 mg, 2 times / day
Route: oral
Route: multiple
Dose: 45 mg, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: multiple sclerosis
Sex: M+F
Food Status: UNKNOWN
Population Size: 28
Sources:
Other AEs: Fatigue, Headache...
Other AEs:
Fatigue (3.6%)
Headache (7.1%)
Nasopharyngitis (3.6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fatigue 3.6%
45 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 45 mg, 2 times / day
Route: oral
Route: multiple
Dose: 45 mg, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: multiple sclerosis
Sex: M+F
Food Status: UNKNOWN
Population Size: 28
Sources:
Nasopharyngitis 3.6%
45 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 45 mg, 2 times / day
Route: oral
Route: multiple
Dose: 45 mg, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: multiple sclerosis
Sex: M+F
Food Status: UNKNOWN
Population Size: 28
Sources:
Headache 7.1%
45 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 45 mg, 2 times / day
Route: oral
Route: multiple
Dose: 45 mg, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: multiple sclerosis
Sex: M+F
Food Status: UNKNOWN
Population Size: 28
Sources:
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

OSU6162 of 30-60 mg/day
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: To elucidate a plausible mechanism of action for both enantiomers of OSU6162, it was evaluated the intrinsic actions of (-)- and (+)-OSU6162, and a collection of other antipsychotic and antiparkinsonian agents at 5-HT2A and D2 receptors in functional assays with various degrees of receptor reserve, including cellular proliferation, phosphatidyl inositol hydrolysis, GTPγS and beta-arrestin recruitment assays. Both enantiomers of OSU6162 were medium intrinsic activity partial agonists at 5-HT2A receptors and low intrinsic activity partial agonists at D2 receptors.
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:15:06 UTC 2021
Edited
by admin
on Sat Jun 26 12:15:06 UTC 2021
Record UNII
0D21EQAQQA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OSU-6162
Code English
PNU-96391
Code English
(-)-OSU 6162
Code English
PIPERIDINE, 3-(3-(METHYLSULFONYL)PHENYL)-1-PROPYL-, (3S)-
Systematic Name English
Code System Code Type Description
FDA UNII
0D21EQAQQA
Created by admin on Sat Jun 26 12:15:06 UTC 2021 , Edited by admin on Sat Jun 26 12:15:06 UTC 2021
PRIMARY
CAS
146798-66-5
Created by admin on Sat Jun 26 12:15:06 UTC 2021 , Edited by admin on Sat Jun 26 12:15:06 UTC 2021
PRIMARY
PUBCHEM
9795741
Created by admin on Sat Jun 26 12:15:06 UTC 2021 , Edited by admin on Sat Jun 26 12:15:06 UTC 2021
PRIMARY
WIKIPEDIA
OSU-6162
Created by admin on Sat Jun 26 12:15:06 UTC 2021 , Edited by admin on Sat Jun 26 12:15:06 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
TARGET->PARTIAL AGONIST
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET->PARTIAL AGONIST
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
ACTIVE MOIETY